A 12-year cohort study in Korea involving over 5,400 prostate cancer patients demonstrated that sustained prostate-specific antigen (PSA) screening leads to earlier cancer detection and lowers rates of metastatic disease. The results, published in a major clinical journal, support the value of population-wide PSA monitoring to improve prognosis and reduce prostate cancer mortality. These findings contribute to the ongoing debate regarding screening recommendations and personalized risk management strategies.